The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Suppression of Cancer Cell Growth by Promoting Cyclin D1 Degradation
Open accessAbstract
Summary The cyclin D1 proto-oncoprotein is a crucial regulator in cell cycle progression and aberrant overexpression of cyclin D1 is linked to tumorigenesis of many different cancer types. By screening ubiquitinated cyclin D1 as a substrate with a deubiquitinase library, we have identified USP2 as a specific deubiquitinase for cyclin D1. USP2 directly interacts with cyclin D1 and promotes its stabilization by antagonizing ubiquitin-dependent degradation. Conversely, USP2 knockdown destabilizes cyclin D1 and induces growth arrest in the human cancer lines where cell growth is dependent on cyclin D1 expression. Notably, cyclin D1 is not universally required for cell cycle progression. Inactivation of USP2 has either very mild effects on cell growth in normal human fibroblasts or no effect in the cancer cells that do not express cyclin D1. These findings suggest that targeting USP2 is an effective approach to induce growth suppression in the cancer cells addicted to cyclin D1 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 4×
“…as a proto-oncogene that is activated by chromosomal translocation in human B cell tumors or overexpressed in many types of human cancers, including lymphoid, breast, esophageal, lung, and bladder tumors (Diehl, 2002; Sherr, 1996; Landis et al., 2006; Lee and Sicinski, 2006; Li et al., 2006).”
InfluentialA genomic and functional inventory of deubiquitinating enzymes.
Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.11.007 · Cited by 1,854
p53 ubiquitination: Mdm2 and beyond
Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924
Self-citationA dynamic role of HAUSP in the p53-Mdm2 pathway
Li, M., Brooks, C. L., Kon, N., & Gu, W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00157-1 · Cited by 679 · cited 2×
“A number of Dubs have been identified that specifically regulate the stability or function of various cellular factors, such as p53, Mdm2/Mdmx, c-Myc, TRAF2, BRCA2, and FANCD2 (Li et al., 2002, 2004; Cummins and Vogelstein, 2004; Meulmeester et al., 2005; Popov et al., 2007; Brummelkamp et al., 2003; Nijman et al., 20…”
Self-citationPhosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4-αB Crystallin Complex
Lin, D. I., Barbash, O., Kumar, K. G. S., Weber, J. D., Harper, J. W., Klein-Szanto, A. J. P., Rustgi, A., Fuchs, S. Y., & Diehl, J. A. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.09.007 · Cited by 349
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329
Meulmeester, E., Maurice, M. M., Boutell, C., Teunisse, A. F. A. S., Ovaa, H., Abraham, T. E., Dirks, R. W., & Jochemsen, A. G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.024 · Cited by 260
Cited by
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Rustgi, A. K., & El-Serag, H. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1314530 · Cited by 1,243
Deubiquitinases in cancer: new functions and therapeutic options
Fraile, J. M., Quesada, V, Rodríguez, D., Freije, J. M. P., & López-Otín, C. (2012) · Oncogene · doi:10.1038/onc.2011.443 · Cited by 453
Ubiquitin–proteasome system (UPS) as a target for anticancer treatment
Park, J., Cho, J., & Song, E. J. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01281-8 · Cited by 408
Kapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Talpaz, M., & Donato, N. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1530 · Cited by 383
The molecular pathogenesis of head and neck squamous cell carcinoma
Rothenberg, S. M., & Ellisen, L. W. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59889 · Cited by 363
Dewson, G., Eichhorn, P. J. A., & Komander, D. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00633-y · Cited by 326
Deubiquitinase inhibition as a cancer therapeutic strategy
D'Arcy, P., Wang, X., & Linder, S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.002 · Cited by 310
The double dealing of cyclin D1
Tchakarska, G., & Sola, B. (2020) · Cell Cycle · doi:10.1080/15384101.2019.1706903 · Cited by 278
“This can be achieved by the knockdown of USP2 coding a cyclin D1-specific deubiquitylase or by the use of inhibitors [35,36].”
BackgroundPathological implication of protein post-translational modifications in cancer
Pan, S., & Chen, R. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101097 · Cited by 263
Structure-guided development of a potent and selective non-covalent active-site inhibitor of USP7.
Lamberto, I., Liu, X., Seo, H.-S., Schauer, N. J., Iacob, R. E., Hu, W., Das, D., Mikhailova, T., Weisberg, E. L., Engen, J. R., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.003 · Cited by 192
“, 2011) and USP2 and USP8 are reported to stabilize oncogenic proteins cyclin D1(Shan et al., 2009) and mutant EGFR,(Byun et al.”
BackgroundUbiquitin-specific protease 22 is a deubiquitinase of CCNB1
Lin, Z., Tan, C., Qiu, Q., Kong, S., Yang, H., Zhao, F., Liu, Z., Li, J., Kong, Q., Gao, B., et al. (2015) · Cell Discovery · doi:10.1038/celldisc.2015.28 · Cited by 90
The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL
Nelson, J. K., Sorrentino, V., Avagliano Trezza, R., Heride, C., Urbe, S., Distel, B., & Zelcer, N. (2016) · Circulation Research · doi:10.1161/circresaha.115.307298 · Cited by 51
Balut, C. M., Loch, C. M., & Devor, D. C. (2011) · The FASEB Journal · doi:10.1096/fj.11-187005 · Cited by 49
miR-150 inhibits terminal erythroid, proliferation and differentiation.
Sun, Z., Wang, Y., Han, X., Zhao, X., Peng, Y., Li, Y., Peng, M., Song, J., Wu, K., Sun, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5824 · Cited by 32
Metadata
- Authors
- Shan, J., Zhao, W., & Gu, W.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 36
- Issue
- 3
- Pages
- 469-476
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W2013035261
- Cited by
- 229
- References
- 7
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.